Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.60 |
| ▸ | HTR6 | P50406 | 6/20 | 0.60 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13478810 | 0.98 | HTR6 (0.60) | HRH1HTR6SCARB1CA1CA2 | |
| SCHEMBL3150253 | 0.83 | HTR6 (0.57) | HRH1HTR6SCARB1 | |
| SCHEMBL14217957 | 0.83 | HTR6 (0.52) | HRH1HTR6CA1CA2CNR2 | |
| SCHEMBL14217953 | 0.83 | SCARB1 (0.49) | HRH1HTR6SCARB1CA1CA2 | |
| SCHEMBL2024144 | 0.82 | HRH1 (0.55) | HRH1HTR6SCARB1CNR2 | |
| SCHEMBL19015842 | 0.82 | HRH1 (0.55) | HRH1HTR6SCARB1CNR2 | |
| Hydrochloric Acid SCHEMBL2025854 | 0.81 | HTR6 (0.54) | HRH1HTR6SCARB1CNR2 | |
| Hydrochloric Acid SCHEMBL2024394 | 0.81 | HTR6 (0.54) | HRH1HTR6SCARB1CNR2 | |
| Hydrochloric Acid SCHEMBL17592674 | 0.81 | HTR6 (0.54) | HRH1HTR6SCARB1CNR2 | |
| SCHEMBL13478801 | 0.81 | HTR6 (0.55) | HRH1HTR6CA1CA2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |